Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Advanced Tumor

Treatments: Drug: ZD1839; Drug: AZD2171

Study type: Interventional

Funder types: Industry

Identifiers

NCT00502060

D8480C00004

Details and patient eligibility

About

Phase I AZD2171 in combination with ZD1839 study recruiting patients with advanced cancer

Enrollment: 65 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• tumor progressed on standard therapy or ineligible for standard therapy
• life expectancy of 12 weeks or more
• WHO performance status 0-2

Exclusion criteria

• History of active interstitial lung disease

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)